| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Research Abstract |
We showed that both phosphodiesterase III inhibitors and Rho kinase inhibitors administered just before reperfusion protect against liver ischemia reperfusion injury and apoptosis. This protective effect was attenuated by wortmannin, a PI3K-Akt inhibitor, PD-98059, an ERK inhibitor, or L-NAME, a eNOS inhibitor. Both phosphodiesterase III inhibitors and Rho kinase inhibitors administered just before reperfusion activated PI3K-Akt, ERK, or eNOS. Thus both phosphodiesterase III inhibitors and Rho kinase inhibitors could have postconditioning effects via PI3K-Akt, ERK, or eNOS activation.
|
